Physician profile
Diego E Marra
NPI 1023174414
$1,746.53
in general payments reported to CMS, 2019-2025
16 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $85.73 · 2021: $326 · 2022: $228 · 2023: $507 · 2024: $185 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $628 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $628.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $208.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $471.15 | 2019-2024 | |
| Lilly USA, LLC | $336.33 | 2021-2024 | Olumiant, Taltz |
| Mayne Pharma Commercial LLC | $223.92 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $126.43 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $117.19 | 2019 | |
| Amgen INC. | $111.88 | 2019-2021 | |
| Incyte Corporation | $80.65 | 2023-2025 | Opzelura |
| Leo Pharma INC. | $65.38 | 2020-2021 | |
| Janssen Biotech, INC. | $63.69 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Almirall LLC | $45.80 | 2021-2024 | Seysara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.95 | 2023 | Cyltezo |
| Paratek Pharmaceuticals, INC. | $20.32 | 2025 | Nuzyra |
| Genzyme Corporation | $19.87 | 2022 | |
| Botanix Sb INC | $14.44 | 2025 | Sofdra |
| Regeneron Healthcare Solutions, INC. | $13.52 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $13.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diego Marra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.